nodes	percent_of_prediction	percent_of_DWPC	metapath
Irbesartan—CYP2C8—Sorafenib—thyroid cancer	0.0689	0.207	CbGbCtD
Irbesartan—CYP1A2—Sorafenib—thyroid cancer	0.0534	0.161	CbGbCtD
Irbesartan—CYP2C9—Sorafenib—thyroid cancer	0.0481	0.145	CbGbCtD
Irbesartan—CYP3A4—Vandetanib—thyroid cancer	0.0464	0.14	CbGbCtD
Irbesartan—CYP2D6—Sorafenib—thyroid cancer	0.044	0.132	CbGbCtD
Irbesartan—CYP3A4—Sorafenib—thyroid cancer	0.028	0.0841	CbGbCtD
Irbesartan—CYP2D6—Doxorubicin—thyroid cancer	0.0267	0.0803	CbGbCtD
Irbesartan—CYP3A4—Doxorubicin—thyroid cancer	0.017	0.051	CbGbCtD
Irbesartan—JUN—neck—thyroid cancer	0.00535	0.124	CbGeAlD
Irbesartan—JUN—saliva-secreting gland—thyroid cancer	0.00417	0.0966	CbGeAlD
Irbesartan—AGTR1—neck—thyroid cancer	0.00403	0.0932	CbGeAlD
Irbesartan—EDNRA—trachea—thyroid cancer	0.00353	0.0816	CbGeAlD
Irbesartan—JUN—trachea—thyroid cancer	0.00322	0.0745	CbGeAlD
Irbesartan—EDNRA—thyroid gland—thyroid cancer	0.00279	0.0646	CbGeAlD
Irbesartan—JUN—thyroid gland—thyroid cancer	0.00255	0.0589	CbGeAlD
Irbesartan—AGTR1—trachea—thyroid cancer	0.00242	0.0561	CbGeAlD
Irbesartan—JUN—head—thyroid cancer	0.00226	0.0523	CbGeAlD
Irbesartan—AGTR1—thyroid gland—thyroid cancer	0.00192	0.0444	CbGeAlD
Irbesartan—EDNRA—lymph node—thyroid cancer	0.00173	0.0401	CbGeAlD
Irbesartan—AGTR1—head—thyroid cancer	0.0017	0.0394	CbGeAlD
Irbesartan—JUN—lymph node—thyroid cancer	0.00158	0.0366	CbGeAlD
Irbesartan—AGTR1—lymph node—thyroid cancer	0.00119	0.0276	CbGeAlD
Irbesartan—PTGS1—trachea—thyroid cancer	0.00107	0.0247	CbGeAlD
Irbesartan—CYP1A2—thyroid gland—thyroid cancer	0.000973	0.0225	CbGeAlD
Irbesartan—PTGS1—thyroid gland—thyroid cancer	0.000843	0.0195	CbGeAlD
Irbesartan—PTGS1—head—thyroid cancer	0.000748	0.0173	CbGeAlD
Irbesartan—Pain—Sorafenib—thyroid cancer	0.000628	0.00167	CcSEcCtD
Irbesartan—Constipation—Sorafenib—thyroid cancer	0.000628	0.00167	CcSEcCtD
Irbesartan—Pulmonary oedema—Doxorubicin—thyroid cancer	0.000626	0.00166	CcSEcCtD
Irbesartan—CYP2D6—head—thyroid cancer	0.000615	0.0142	CbGeAlD
Irbesartan—Gastrointestinal pain—Sorafenib—thyroid cancer	0.0006	0.00159	CcSEcCtD
Irbesartan—Hot flush—Epirubicin—thyroid cancer	0.00059	0.00157	CcSEcCtD
Irbesartan—Increased appetite—Epirubicin—thyroid cancer	0.000587	0.00156	CcSEcCtD
Irbesartan—Diabetes mellitus—Doxorubicin—thyroid cancer	0.000587	0.00156	CcSEcCtD
Irbesartan—Menopausal symptoms—Epirubicin—thyroid cancer	0.000585	0.00155	CcSEcCtD
Irbesartan—Hepatic function abnormal—Doxorubicin—thyroid cancer	0.000584	0.00155	CcSEcCtD
Irbesartan—Urticaria—Sorafenib—thyroid cancer	0.000583	0.00155	CcSEcCtD
Irbesartan—Photosensitivity—Doxorubicin—thyroid cancer	0.000582	0.00154	CcSEcCtD
Irbesartan—Abdominal pain—Sorafenib—thyroid cancer	0.00058	0.00154	CcSEcCtD
Irbesartan—Body temperature increased—Sorafenib—thyroid cancer	0.00058	0.00154	CcSEcCtD
Irbesartan—Renal impairment—Epirubicin—thyroid cancer	0.00058	0.00154	CcSEcCtD
Irbesartan—Cerebrovascular accident—Epirubicin—thyroid cancer	0.000563	0.00149	CcSEcCtD
Irbesartan—Hyponatraemia—Epirubicin—thyroid cancer	0.000554	0.00147	CcSEcCtD
Irbesartan—Hot flush—Doxorubicin—thyroid cancer	0.000546	0.00145	CcSEcCtD
Irbesartan—Increased appetite—Doxorubicin—thyroid cancer	0.000543	0.00144	CcSEcCtD
Irbesartan—Affect lability—Epirubicin—thyroid cancer	0.000543	0.00144	CcSEcCtD
Irbesartan—Menopausal symptoms—Doxorubicin—thyroid cancer	0.000541	0.00144	CcSEcCtD
Irbesartan—Hypersensitivity—Sorafenib—thyroid cancer	0.000541	0.00144	CcSEcCtD
Irbesartan—Renal impairment—Doxorubicin—thyroid cancer	0.000537	0.00142	CcSEcCtD
Irbesartan—Face oedema—Epirubicin—thyroid cancer	0.000533	0.00141	CcSEcCtD
Irbesartan—Asthenia—Sorafenib—thyroid cancer	0.000527	0.0014	CcSEcCtD
Irbesartan—PTGS1—lymph node—thyroid cancer	0.000524	0.0121	CbGeAlD
Irbesartan—Mood swings—Epirubicin—thyroid cancer	0.000523	0.00139	CcSEcCtD
Irbesartan—Cerebrovascular accident—Doxorubicin—thyroid cancer	0.000521	0.00138	CcSEcCtD
Irbesartan—Pruritus—Sorafenib—thyroid cancer	0.000519	0.00138	CcSEcCtD
Irbesartan—Hyponatraemia—Doxorubicin—thyroid cancer	0.000513	0.00136	CcSEcCtD
Irbesartan—Liver function test abnormal—Epirubicin—thyroid cancer	0.000509	0.00135	CcSEcCtD
Irbesartan—Orthostatic hypotension—Epirubicin—thyroid cancer	0.000504	0.00134	CcSEcCtD
Irbesartan—Abdominal pain upper—Epirubicin—thyroid cancer	0.000504	0.00134	CcSEcCtD
Irbesartan—Affect lability—Doxorubicin—thyroid cancer	0.000503	0.00133	CcSEcCtD
Irbesartan—Hypokalaemia—Epirubicin—thyroid cancer	0.000502	0.00133	CcSEcCtD
Irbesartan—Diarrhoea—Sorafenib—thyroid cancer	0.000502	0.00133	CcSEcCtD
Irbesartan—Breast disorder—Epirubicin—thyroid cancer	0.000499	0.00132	CcSEcCtD
Irbesartan—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	0.000497	0.00132	CcSEcCtD
Irbesartan—Nasopharyngitis—Epirubicin—thyroid cancer	0.000493	0.00131	CcSEcCtD
Irbesartan—Face oedema—Doxorubicin—thyroid cancer	0.000493	0.00131	CcSEcCtD
Irbesartan—Muscular weakness—Epirubicin—thyroid cancer	0.000487	0.00129	CcSEcCtD
Irbesartan—Dizziness—Sorafenib—thyroid cancer	0.000485	0.00129	CcSEcCtD
Irbesartan—Mood swings—Doxorubicin—thyroid cancer	0.000484	0.00128	CcSEcCtD
Irbesartan—Abdominal distension—Epirubicin—thyroid cancer	0.00048	0.00127	CcSEcCtD
Irbesartan—Influenza—Epirubicin—thyroid cancer	0.000477	0.00127	CcSEcCtD
Irbesartan—Asthma—Epirubicin—thyroid cancer	0.000477	0.00127	CcSEcCtD
Irbesartan—Dysphagia—Epirubicin—thyroid cancer	0.000477	0.00127	CcSEcCtD
Irbesartan—Liver function test abnormal—Doxorubicin—thyroid cancer	0.000471	0.00125	CcSEcCtD
Irbesartan—Pancreatitis—Epirubicin—thyroid cancer	0.000468	0.00124	CcSEcCtD
Irbesartan—Vomiting—Sorafenib—thyroid cancer	0.000467	0.00124	CcSEcCtD
Irbesartan—Abdominal pain upper—Doxorubicin—thyroid cancer	0.000466	0.00124	CcSEcCtD
Irbesartan—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.000466	0.00124	CcSEcCtD
Irbesartan—Hypokalaemia—Doxorubicin—thyroid cancer	0.000465	0.00123	CcSEcCtD
Irbesartan—Angina pectoris—Epirubicin—thyroid cancer	0.000465	0.00123	CcSEcCtD
Irbesartan—Rash—Sorafenib—thyroid cancer	0.000463	0.00123	CcSEcCtD
Irbesartan—Dermatitis—Sorafenib—thyroid cancer	0.000462	0.00123	CcSEcCtD
Irbesartan—Breast disorder—Doxorubicin—thyroid cancer	0.000461	0.00122	CcSEcCtD
Irbesartan—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.00046	0.00122	CcSEcCtD
Irbesartan—Headache—Sorafenib—thyroid cancer	0.00046	0.00122	CcSEcCtD
Irbesartan—Nasopharyngitis—Doxorubicin—thyroid cancer	0.000457	0.00121	CcSEcCtD
Irbesartan—Muscular weakness—Doxorubicin—thyroid cancer	0.00045	0.0012	CcSEcCtD
Irbesartan—Neutropenia—Epirubicin—thyroid cancer	0.000446	0.00118	CcSEcCtD
Irbesartan—Abdominal distension—Doxorubicin—thyroid cancer	0.000444	0.00118	CcSEcCtD
Irbesartan—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.000443	0.00118	CcSEcCtD
Irbesartan—Influenza—Doxorubicin—thyroid cancer	0.000441	0.00117	CcSEcCtD
Irbesartan—Asthma—Doxorubicin—thyroid cancer	0.000441	0.00117	CcSEcCtD
Irbesartan—Dysphagia—Doxorubicin—thyroid cancer	0.000441	0.00117	CcSEcCtD
Irbesartan—Nausea—Sorafenib—thyroid cancer	0.000436	0.00116	CcSEcCtD
Irbesartan—Photosensitivity reaction—Epirubicin—thyroid cancer	0.000435	0.00116	CcSEcCtD
Irbesartan—Weight increased—Epirubicin—thyroid cancer	0.000434	0.00115	CcSEcCtD
Irbesartan—Pancreatitis—Doxorubicin—thyroid cancer	0.000433	0.00115	CcSEcCtD
Irbesartan—Hyperglycaemia—Epirubicin—thyroid cancer	0.00043	0.00114	CcSEcCtD
Irbesartan—Angina pectoris—Doxorubicin—thyroid cancer	0.00043	0.00114	CcSEcCtD
Irbesartan—Pneumonia—Epirubicin—thyroid cancer	0.000428	0.00114	CcSEcCtD
Irbesartan—Renal failure—Epirubicin—thyroid cancer	0.000418	0.00111	CcSEcCtD
Irbesartan—Jaundice—Epirubicin—thyroid cancer	0.000415	0.0011	CcSEcCtD
Irbesartan—Conjunctivitis—Epirubicin—thyroid cancer	0.000413	0.0011	CcSEcCtD
Irbesartan—Urinary tract infection—Epirubicin—thyroid cancer	0.000413	0.0011	CcSEcCtD
Irbesartan—Neutropenia—Doxorubicin—thyroid cancer	0.000413	0.0011	CcSEcCtD
Irbesartan—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.00041	0.00109	CcSEcCtD
Irbesartan—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.000403	0.00107	CcSEcCtD
Irbesartan—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000402	0.00107	CcSEcCtD
Irbesartan—Weight increased—Doxorubicin—thyroid cancer	0.000402	0.00107	CcSEcCtD
Irbesartan—Epistaxis—Epirubicin—thyroid cancer	0.000401	0.00106	CcSEcCtD
Irbesartan—Hyperglycaemia—Doxorubicin—thyroid cancer	0.000398	0.00106	CcSEcCtD
Irbesartan—Agranulocytosis—Epirubicin—thyroid cancer	0.000397	0.00105	CcSEcCtD
Irbesartan—Pneumonia—Doxorubicin—thyroid cancer	0.000396	0.00105	CcSEcCtD
Irbesartan—Bradycardia—Epirubicin—thyroid cancer	0.000389	0.00103	CcSEcCtD
Irbesartan—Renal failure—Doxorubicin—thyroid cancer	0.000387	0.00103	CcSEcCtD
Irbesartan—Jaundice—Doxorubicin—thyroid cancer	0.000384	0.00102	CcSEcCtD
Irbesartan—Rhinitis—Epirubicin—thyroid cancer	0.000383	0.00102	CcSEcCtD
Irbesartan—Urinary tract infection—Doxorubicin—thyroid cancer	0.000382	0.00102	CcSEcCtD
Irbesartan—Conjunctivitis—Doxorubicin—thyroid cancer	0.000382	0.00102	CcSEcCtD
Irbesartan—Hepatitis—Epirubicin—thyroid cancer	0.000382	0.00101	CcSEcCtD
Irbesartan—Hypoaesthesia—Epirubicin—thyroid cancer	0.00038	0.00101	CcSEcCtD
Irbesartan—Pharyngitis—Epirubicin—thyroid cancer	0.000379	0.00101	CcSEcCtD
Irbesartan—Urinary tract disorder—Epirubicin—thyroid cancer	0.000377	0.001	CcSEcCtD
Irbesartan—Oedema peripheral—Epirubicin—thyroid cancer	0.000376	0.000998	CcSEcCtD
Irbesartan—Connective tissue disorder—Epirubicin—thyroid cancer	0.000375	0.000996	CcSEcCtD
Irbesartan—Urethral disorder—Epirubicin—thyroid cancer	0.000374	0.000993	CcSEcCtD
Irbesartan—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000372	0.000988	CcSEcCtD
Irbesartan—Epistaxis—Doxorubicin—thyroid cancer	0.000371	0.000985	CcSEcCtD
Irbesartan—Visual impairment—Epirubicin—thyroid cancer	0.000368	0.000977	CcSEcCtD
Irbesartan—Agranulocytosis—Doxorubicin—thyroid cancer	0.000367	0.000975	CcSEcCtD
Irbesartan—Bradycardia—Doxorubicin—thyroid cancer	0.00036	0.000955	CcSEcCtD
Irbesartan—Tinnitus—Epirubicin—thyroid cancer	0.000356	0.000945	CcSEcCtD
Irbesartan—Flushing—Epirubicin—thyroid cancer	0.000354	0.000941	CcSEcCtD
Irbesartan—Cardiac disorder—Epirubicin—thyroid cancer	0.000354	0.000941	CcSEcCtD
Irbesartan—Rhinitis—Doxorubicin—thyroid cancer	0.000354	0.00094	CcSEcCtD
Irbesartan—Hepatitis—Doxorubicin—thyroid cancer	0.000353	0.000938	CcSEcCtD
Irbesartan—Hypoaesthesia—Doxorubicin—thyroid cancer	0.000351	0.000933	CcSEcCtD
Irbesartan—Pharyngitis—Doxorubicin—thyroid cancer	0.000351	0.000931	CcSEcCtD
Irbesartan—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000349	0.000926	CcSEcCtD
Irbesartan—Oedema peripheral—Doxorubicin—thyroid cancer	0.000348	0.000924	CcSEcCtD
Irbesartan—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000347	0.000921	CcSEcCtD
Irbesartan—Angiopathy—Epirubicin—thyroid cancer	0.000346	0.000919	CcSEcCtD
Irbesartan—Urethral disorder—Doxorubicin—thyroid cancer	0.000346	0.000919	CcSEcCtD
Irbesartan—Immune system disorder—Epirubicin—thyroid cancer	0.000345	0.000915	CcSEcCtD
Irbesartan—Mediastinal disorder—Epirubicin—thyroid cancer	0.000344	0.000913	CcSEcCtD
Irbesartan—Chills—Epirubicin—thyroid cancer	0.000343	0.000909	CcSEcCtD
Irbesartan—Arrhythmia—Epirubicin—thyroid cancer	0.000341	0.000905	CcSEcCtD
Irbesartan—Visual impairment—Doxorubicin—thyroid cancer	0.00034	0.000904	CcSEcCtD
Irbesartan—Erythema—Epirubicin—thyroid cancer	0.000332	0.000882	CcSEcCtD
Irbesartan—Malnutrition—Epirubicin—thyroid cancer	0.000332	0.000882	CcSEcCtD
Irbesartan—Tinnitus—Doxorubicin—thyroid cancer	0.000329	0.000874	CcSEcCtD
Irbesartan—Flushing—Doxorubicin—thyroid cancer	0.000328	0.00087	CcSEcCtD
Irbesartan—Cardiac disorder—Doxorubicin—thyroid cancer	0.000328	0.00087	CcSEcCtD
Irbesartan—Flatulence—Epirubicin—thyroid cancer	0.000327	0.000869	CcSEcCtD
Irbesartan—Tension—Epirubicin—thyroid cancer	0.000326	0.000866	CcSEcCtD
Irbesartan—Dysgeusia—Epirubicin—thyroid cancer	0.000325	0.000864	CcSEcCtD
Irbesartan—Nervousness—Epirubicin—thyroid cancer	0.000323	0.000857	CcSEcCtD
Irbesartan—Angiopathy—Doxorubicin—thyroid cancer	0.00032	0.000851	CcSEcCtD
Irbesartan—Muscle spasms—Epirubicin—thyroid cancer	0.00032	0.000848	CcSEcCtD
Irbesartan—Immune system disorder—Doxorubicin—thyroid cancer	0.000319	0.000847	CcSEcCtD
Irbesartan—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000318	0.000845	CcSEcCtD
Irbesartan—Chills—Doxorubicin—thyroid cancer	0.000317	0.000841	CcSEcCtD
Irbesartan—Arrhythmia—Doxorubicin—thyroid cancer	0.000316	0.000838	CcSEcCtD
Irbesartan—Vision blurred—Epirubicin—thyroid cancer	0.000313	0.000831	CcSEcCtD
Irbesartan—Ill-defined disorder—Epirubicin—thyroid cancer	0.000308	0.000819	CcSEcCtD
Irbesartan—Malnutrition—Doxorubicin—thyroid cancer	0.000307	0.000816	CcSEcCtD
Irbesartan—Erythema—Doxorubicin—thyroid cancer	0.000307	0.000816	CcSEcCtD
Irbesartan—Anaemia—Epirubicin—thyroid cancer	0.000307	0.000815	CcSEcCtD
Irbesartan—Agitation—Epirubicin—thyroid cancer	0.000305	0.000811	CcSEcCtD
Irbesartan—Flatulence—Doxorubicin—thyroid cancer	0.000303	0.000804	CcSEcCtD
Irbesartan—Tension—Doxorubicin—thyroid cancer	0.000302	0.000801	CcSEcCtD
Irbesartan—Dysgeusia—Doxorubicin—thyroid cancer	0.000301	0.000799	CcSEcCtD
Irbesartan—Malaise—Epirubicin—thyroid cancer	0.0003	0.000796	CcSEcCtD
Irbesartan—Nervousness—Doxorubicin—thyroid cancer	0.000299	0.000793	CcSEcCtD
Irbesartan—Vertigo—Epirubicin—thyroid cancer	0.000299	0.000793	CcSEcCtD
Irbesartan—Syncope—Epirubicin—thyroid cancer	0.000298	0.000791	CcSEcCtD
Irbesartan—Leukopenia—Epirubicin—thyroid cancer	0.000297	0.00079	CcSEcCtD
Irbesartan—Muscle spasms—Doxorubicin—thyroid cancer	0.000296	0.000785	CcSEcCtD
Irbesartan—Loss of consciousness—Epirubicin—thyroid cancer	0.000292	0.000775	CcSEcCtD
Irbesartan—Cough—Epirubicin—thyroid cancer	0.00029	0.00077	CcSEcCtD
Irbesartan—Vision blurred—Doxorubicin—thyroid cancer	0.00029	0.000769	CcSEcCtD
Irbesartan—Hypertension—Epirubicin—thyroid cancer	0.000287	0.000762	CcSEcCtD
Irbesartan—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000285	0.000757	CcSEcCtD
Irbesartan—Anaemia—Doxorubicin—thyroid cancer	0.000284	0.000754	CcSEcCtD
Irbesartan—Arthralgia—Epirubicin—thyroid cancer	0.000283	0.000751	CcSEcCtD
Irbesartan—Chest pain—Epirubicin—thyroid cancer	0.000283	0.000751	CcSEcCtD
Irbesartan—Myalgia—Epirubicin—thyroid cancer	0.000283	0.000751	CcSEcCtD
Irbesartan—Agitation—Doxorubicin—thyroid cancer	0.000283	0.00075	CcSEcCtD
Irbesartan—Anxiety—Epirubicin—thyroid cancer	0.000282	0.000748	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000281	0.000746	CcSEcCtD
Irbesartan—Discomfort—Epirubicin—thyroid cancer	0.00028	0.000742	CcSEcCtD
Irbesartan—Malaise—Doxorubicin—thyroid cancer	0.000277	0.000736	CcSEcCtD
Irbesartan—Dry mouth—Epirubicin—thyroid cancer	0.000277	0.000735	CcSEcCtD
Irbesartan—Vertigo—Doxorubicin—thyroid cancer	0.000276	0.000733	CcSEcCtD
Irbesartan—Syncope—Doxorubicin—thyroid cancer	0.000276	0.000732	CcSEcCtD
Irbesartan—Leukopenia—Doxorubicin—thyroid cancer	0.000275	0.000731	CcSEcCtD
Irbesartan—Oedema—Epirubicin—thyroid cancer	0.000271	0.00072	CcSEcCtD
Irbesartan—Anaphylactic shock—Epirubicin—thyroid cancer	0.000271	0.00072	CcSEcCtD
Irbesartan—Loss of consciousness—Doxorubicin—thyroid cancer	0.00027	0.000717	CcSEcCtD
Irbesartan—Infection—Epirubicin—thyroid cancer	0.000269	0.000715	CcSEcCtD
Irbesartan—Cough—Doxorubicin—thyroid cancer	0.000268	0.000712	CcSEcCtD
Irbesartan—Shock—Epirubicin—thyroid cancer	0.000267	0.000708	CcSEcCtD
Irbesartan—Nervous system disorder—Epirubicin—thyroid cancer	0.000266	0.000706	CcSEcCtD
Irbesartan—Thrombocytopenia—Epirubicin—thyroid cancer	0.000266	0.000705	CcSEcCtD
Irbesartan—Hypertension—Doxorubicin—thyroid cancer	0.000265	0.000705	CcSEcCtD
Irbesartan—Tachycardia—Epirubicin—thyroid cancer	0.000265	0.000703	CcSEcCtD
Irbesartan—Skin disorder—Epirubicin—thyroid cancer	0.000263	0.000699	CcSEcCtD
Irbesartan—Hyperhidrosis—Epirubicin—thyroid cancer	0.000262	0.000696	CcSEcCtD
Irbesartan—Arthralgia—Doxorubicin—thyroid cancer	0.000262	0.000695	CcSEcCtD
Irbesartan—Chest pain—Doxorubicin—thyroid cancer	0.000262	0.000695	CcSEcCtD
Irbesartan—Myalgia—Doxorubicin—thyroid cancer	0.000262	0.000695	CcSEcCtD
Irbesartan—Anxiety—Doxorubicin—thyroid cancer	0.000261	0.000693	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.00026	0.00069	CcSEcCtD
Irbesartan—Discomfort—Doxorubicin—thyroid cancer	0.000259	0.000687	CcSEcCtD
Irbesartan—Anorexia—Epirubicin—thyroid cancer	0.000259	0.000686	CcSEcCtD
Irbesartan—Dry mouth—Doxorubicin—thyroid cancer	0.000256	0.00068	CcSEcCtD
Irbesartan—Hypotension—Epirubicin—thyroid cancer	0.000253	0.000673	CcSEcCtD
Irbesartan—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000251	0.000666	CcSEcCtD
Irbesartan—Oedema—Doxorubicin—thyroid cancer	0.000251	0.000666	CcSEcCtD
Irbesartan—Infection—Doxorubicin—thyroid cancer	0.000249	0.000662	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000247	0.000656	CcSEcCtD
Irbesartan—Shock—Doxorubicin—thyroid cancer	0.000247	0.000655	CcSEcCtD
Irbesartan—Nervous system disorder—Doxorubicin—thyroid cancer	0.000246	0.000653	CcSEcCtD
Irbesartan—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000246	0.000652	CcSEcCtD
Irbesartan—Tachycardia—Doxorubicin—thyroid cancer	0.000245	0.00065	CcSEcCtD
Irbesartan—Skin disorder—Doxorubicin—thyroid cancer	0.000244	0.000647	CcSEcCtD
Irbesartan—Paraesthesia—Epirubicin—thyroid cancer	0.000244	0.000647	CcSEcCtD
Irbesartan—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000243	0.000644	CcSEcCtD
Irbesartan—Dyspnoea—Epirubicin—thyroid cancer	0.000242	0.000642	CcSEcCtD
Irbesartan—Somnolence—Epirubicin—thyroid cancer	0.000241	0.00064	CcSEcCtD
Irbesartan—Anorexia—Doxorubicin—thyroid cancer	0.000239	0.000635	CcSEcCtD
Irbesartan—Dyspepsia—Epirubicin—thyroid cancer	0.000239	0.000634	CcSEcCtD
Irbesartan—Decreased appetite—Epirubicin—thyroid cancer	0.000236	0.000626	CcSEcCtD
Irbesartan—Hypotension—Doxorubicin—thyroid cancer	0.000235	0.000622	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000234	0.000622	CcSEcCtD
Irbesartan—Fatigue—Epirubicin—thyroid cancer	0.000234	0.000621	CcSEcCtD
Irbesartan—Constipation—Epirubicin—thyroid cancer	0.000232	0.000616	CcSEcCtD
Irbesartan—Pain—Epirubicin—thyroid cancer	0.000232	0.000616	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000229	0.000607	CcSEcCtD
Irbesartan—Paraesthesia—Doxorubicin—thyroid cancer	0.000225	0.000598	CcSEcCtD
Irbesartan—Dyspnoea—Doxorubicin—thyroid cancer	0.000224	0.000594	CcSEcCtD
Irbesartan—Feeling abnormal—Epirubicin—thyroid cancer	0.000224	0.000593	CcSEcCtD
Irbesartan—Somnolence—Doxorubicin—thyroid cancer	0.000223	0.000592	CcSEcCtD
Irbesartan—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000222	0.000589	CcSEcCtD
Irbesartan—Dyspepsia—Doxorubicin—thyroid cancer	0.000221	0.000586	CcSEcCtD
Irbesartan—Decreased appetite—Doxorubicin—thyroid cancer	0.000218	0.000579	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000217	0.000575	CcSEcCtD
Irbesartan—Fatigue—Doxorubicin—thyroid cancer	0.000216	0.000574	CcSEcCtD
Irbesartan—Urticaria—Epirubicin—thyroid cancer	0.000215	0.000572	CcSEcCtD
Irbesartan—Constipation—Doxorubicin—thyroid cancer	0.000215	0.00057	CcSEcCtD
Irbesartan—Pain—Doxorubicin—thyroid cancer	0.000215	0.00057	CcSEcCtD
Irbesartan—Body temperature increased—Epirubicin—thyroid cancer	0.000214	0.000569	CcSEcCtD
Irbesartan—Abdominal pain—Epirubicin—thyroid cancer	0.000214	0.000569	CcSEcCtD
Irbesartan—Feeling abnormal—Doxorubicin—thyroid cancer	0.000207	0.000549	CcSEcCtD
Irbesartan—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000205	0.000545	CcSEcCtD
Irbesartan—Hypersensitivity—Epirubicin—thyroid cancer	0.0002	0.00053	CcSEcCtD
Irbesartan—Urticaria—Doxorubicin—thyroid cancer	0.000199	0.000529	CcSEcCtD
Irbesartan—Abdominal pain—Doxorubicin—thyroid cancer	0.000198	0.000527	CcSEcCtD
Irbesartan—Body temperature increased—Doxorubicin—thyroid cancer	0.000198	0.000527	CcSEcCtD
Irbesartan—AGTR1—Signaling by GPCR—PTCH1—thyroid cancer	0.000196	0.000791	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—NDUFA13—thyroid cancer	0.000195	0.000787	CbGpPWpGaD
Irbesartan—Asthenia—Epirubicin—thyroid cancer	0.000195	0.000517	CcSEcCtD
Irbesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	0.000193	0.000781	CbGpPWpGaD
Irbesartan—JUN—PDGFR-beta signaling pathway—KRAS—thyroid cancer	0.000192	0.000775	CbGpPWpGaD
Irbesartan—Pruritus—Epirubicin—thyroid cancer	0.000192	0.000509	CcSEcCtD
Irbesartan—JUN—Signaling by NOTCH—TP53—thyroid cancer	0.00019	0.000769	CbGpPWpGaD
Irbesartan—JUN—DNA Damage Response (only ATM dependent)—TP53—thyroid cancer	0.00019	0.000769	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—CALCA—thyroid cancer	0.00019	0.000767	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—PTEN—thyroid cancer	0.000189	0.000764	CbGpPWpGaD
Irbesartan—JUN—Androgen receptor signaling pathway—AKT1—thyroid cancer	0.000189	0.000763	CbGpPWpGaD
Irbesartan—JUN—ErbB1 downstream signaling—HRAS—thyroid cancer	0.000188	0.000757	CbGpPWpGaD
Irbesartan—JUN—Senescence and Autophagy in Cancer—HRAS—thyroid cancer	0.000188	0.000757	CbGpPWpGaD
Irbesartan—JUN—TCR Signaling Pathway—AKT1—thyroid cancer	0.000187	0.000757	CbGpPWpGaD
Irbesartan—CYP1A2—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000187	0.000756	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TCF7L1—thyroid cancer	0.000186	0.000751	CbGpPWpGaD
Irbesartan—Diarrhoea—Epirubicin—thyroid cancer	0.000186	0.000493	CcSEcCtD
Irbesartan—JUN—Focal Adhesion—CCND1—thyroid cancer	0.000185	0.000748	CbGpPWpGaD
Irbesartan—Hypersensitivity—Doxorubicin—thyroid cancer	0.000185	0.000491	CcSEcCtD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	0.000185	0.000745	CbGpPWpGaD
Irbesartan—JUN—TNF alpha Signaling Pathway—AKT1—thyroid cancer	0.000184	0.000743	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—CHST14—thyroid cancer	0.000183	0.00074	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—CDK1—thyroid cancer	0.000183	0.000739	CbGpPWpGaD
Irbesartan—JUN—DNA Damage Response (only ATM dependent)—HRAS—thyroid cancer	0.000182	0.000735	CbGpPWpGaD
Irbesartan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	0.00018	0.000728	CbGpPWpGaD
Irbesartan—Asthenia—Doxorubicin—thyroid cancer	0.00018	0.000478	CcSEcCtD
Irbesartan—Dizziness—Epirubicin—thyroid cancer	0.000179	0.000476	CcSEcCtD
Irbesartan—AGTR1—Signaling by GPCR—SST—thyroid cancer	0.000179	0.000723	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—PTEN—thyroid cancer	0.000179	0.000722	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	0.000178	0.000719	CbGpPWpGaD
Irbesartan—Pruritus—Doxorubicin—thyroid cancer	0.000178	0.000471	CcSEcCtD
Irbesartan—JUN—Oxidative Stress Induced Senescence—TP53—thyroid cancer	0.000177	0.000717	CbGpPWpGaD
Irbesartan—JUN—B Cell Receptor Signaling Pathway—AKT1—thyroid cancer	0.000177	0.000713	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—NRAS—thyroid cancer	0.000176	0.000711	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—IFNA2—thyroid cancer	0.000176	0.00071	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000174	0.000704	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TSHR—thyroid cancer	0.000173	0.0007	CbGpPWpGaD
Irbesartan—Vomiting—Epirubicin—thyroid cancer	0.000172	0.000458	CcSEcCtD
Irbesartan—AGTR1—Signaling by GPCR—CALCA—thyroid cancer	0.000172	0.000696	CbGpPWpGaD
Irbesartan—Diarrhoea—Doxorubicin—thyroid cancer	0.000172	0.000456	CcSEcCtD
Irbesartan—Rash—Epirubicin—thyroid cancer	0.000171	0.000454	CcSEcCtD
Irbesartan—JUN—Circadian rythm related genes—PTEN—thyroid cancer	0.000171	0.00069	CbGpPWpGaD
Irbesartan—Dermatitis—Epirubicin—thyroid cancer	0.000171	0.000454	CcSEcCtD
Irbesartan—EDNRA—Signaling Pathways—PRKAR1A—thyroid cancer	0.000171	0.000689	CbGpPWpGaD
Irbesartan—Headache—Epirubicin—thyroid cancer	0.00017	0.000451	CcSEcCtD
Irbesartan—JUN—Toll-like Receptor Signaling Pathway—AKT1—thyroid cancer	0.00017	0.000685	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—NRAS—thyroid cancer	0.000169	0.000682	CbGpPWpGaD
Irbesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	0.000167	0.000672	CbGpPWpGaD
Irbesartan—Dizziness—Doxorubicin—thyroid cancer	0.000166	0.000441	CcSEcCtD
Irbesartan—JUN—ErbB1 downstream signaling—AKT1—thyroid cancer	0.000166	0.000669	CbGpPWpGaD
Irbesartan—CYP2D6—Biological oxidations—RXRA—thyroid cancer	0.000166	0.000668	CbGpPWpGaD
Irbesartan—JUN—Integrated Breast Cancer Pathway—KRAS—thyroid cancer	0.000165	0.000666	CbGpPWpGaD
Irbesartan—CYP2C9—Biological oxidations—RXRA—thyroid cancer	0.000164	0.000662	CbGpPWpGaD
Irbesartan—JUN—TGF-beta Signaling Pathway—TP53—thyroid cancer	0.000163	0.00066	CbGpPWpGaD
Irbesartan—JUN—PDGFR-beta signaling pathway—HRAS—thyroid cancer	0.000163	0.000659	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MEN1—thyroid cancer	0.000163	0.000658	CbGpPWpGaD
Irbesartan—Nausea—Epirubicin—thyroid cancer	0.000161	0.000428	CcSEcCtD
Irbesartan—JUN—DNA Damage Response (only ATM dependent)—AKT1—thyroid cancer	0.000161	0.000649	CbGpPWpGaD
Irbesartan—Vomiting—Doxorubicin—thyroid cancer	0.00016	0.000424	CcSEcCtD
Irbesartan—Rash—Doxorubicin—thyroid cancer	0.000158	0.00042	CcSEcCtD
Irbesartan—Dermatitis—Doxorubicin—thyroid cancer	0.000158	0.00042	CcSEcCtD
Irbesartan—JUN—Immune System—TPR—thyroid cancer	0.000157	0.000635	CbGpPWpGaD
Irbesartan—Headache—Doxorubicin—thyroid cancer	0.000157	0.000417	CcSEcCtD
Irbesartan—AGTR1—Signaling by GPCR—CDK1—thyroid cancer	0.000156	0.00063	CbGpPWpGaD
Irbesartan—JUN—EGF/EGFR Signaling Pathway—KRAS—thyroid cancer	0.000156	0.00063	CbGpPWpGaD
Irbesartan—JUN—Immune System—LGALS3—thyroid cancer	0.000156	0.00063	CbGpPWpGaD
Irbesartan—JUN—Direct p53 effectors—TP53—thyroid cancer	0.000156	0.000629	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	0.000156	0.000628	CbGpPWpGaD
Irbesartan—JUN—Immune System—PRKAR1A—thyroid cancer	0.000155	0.000625	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—KRAS—thyroid cancer	0.000152	0.000612	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—TPR—thyroid cancer	0.000151	0.000608	CbGpPWpGaD
Irbesartan—Nausea—Doxorubicin—thyroid cancer	0.000149	0.000396	CcSEcCtD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000149	0.000602	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PRKAR1A—thyroid cancer	0.000148	0.000598	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—MINPP1—thyroid cancer	0.000148	0.000598	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—HPGD—thyroid cancer	0.000148	0.000597	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—PTCH1—thyroid cancer	0.000147	0.000595	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—NRG1—thyroid cancer	0.000147	0.000593	CbGpPWpGaD
Irbesartan—JUN—Integrated Breast Cancer Pathway—TP53—thyroid cancer	0.000147	0.000592	CbGpPWpGaD
Irbesartan—JUN—BDNF signaling pathway—HRAS—thyroid cancer	0.000146	0.000588	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—KRAS—thyroid cancer	0.000145	0.000587	CbGpPWpGaD
Irbesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	0.000142	0.000571	CbGpPWpGaD
Irbesartan—CYP1A2—Biological oxidations—RXRA—thyroid cancer	0.00014	0.000566	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TCF7L1—thyroid cancer	0.000139	0.000561	CbGpPWpGaD
Irbesartan—JUN—TGF-beta Signaling Pathway—AKT1—thyroid cancer	0.000138	0.000557	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	0.000137	0.000552	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TSHR—thyroid cancer	0.000136	0.000549	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—SST—thyroid cancer	0.000135	0.000544	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—TP53—thyroid cancer	0.000135	0.000544	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	0.000134	0.000541	CbGpPWpGaD
Irbesartan—JUN—Insulin Signaling—HRAS—thyroid cancer	0.000134	0.000541	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PRKAR1A—thyroid cancer	0.000134	0.00054	CbGpPWpGaD
Irbesartan—JUN—EGF/EGFR Signaling Pathway—HRAS—thyroid cancer	0.000133	0.000535	CbGpPWpGaD
Irbesartan—JUN—Regulation of toll-like receptor signaling pathway—AKT1—thyroid cancer	0.000132	0.000534	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CALCA—thyroid cancer	0.00013	0.000524	CbGpPWpGaD
Irbesartan—JUN—BDNF signaling pathway—AKT1—thyroid cancer	0.000129	0.000519	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MEN1—thyroid cancer	0.000128	0.000517	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—NDUFA13—thyroid cancer	0.000126	0.000508	CbGpPWpGaD
Irbesartan—JUN—Cellular Senescence—TP53—thyroid cancer	0.000124	0.000501	CbGpPWpGaD
Irbesartan—JUN—Integrated Breast Cancer Pathway—AKT1—thyroid cancer	0.000124	0.0005	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—HRAS—thyroid cancer	0.000124	0.000499	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—MINPP1—thyroid cancer	0.000122	0.000491	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	0.000122	0.000491	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—MINPP1—thyroid cancer	0.000121	0.000487	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.00012	0.000484	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CHST14—thyroid cancer	0.000118	0.000478	CbGpPWpGaD
Irbesartan—JUN—Insulin Signaling—AKT1—thyroid cancer	0.000118	0.000477	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CDK1—thyroid cancer	0.000118	0.000474	CbGpPWpGaD
Irbesartan—JUN—EGF/EGFR Signaling Pathway—AKT1—thyroid cancer	0.000117	0.000473	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—HRAS—thyroid cancer	0.000117	0.000471	CbGpPWpGaD
Irbesartan—JUN—Circadian rythm related genes—TP53—thyroid cancer	0.000117	0.000471	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PTCH1—thyroid cancer	0.000116	0.000467	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	0.000114	0.00046	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—AKT1—thyroid cancer	0.000114	0.000459	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—SLC5A5—thyroid cancer	0.000113	0.000455	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—AKT1—thyroid cancer	0.000109	0.00044	CbGpPWpGaD
Irbesartan—CYP3A4—Biological oxidations—RXRA—thyroid cancer	0.000108	0.000437	CbGpPWpGaD
Irbesartan—JUN—Immune System—CDK1—thyroid cancer	0.000107	0.00043	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—SST—thyroid cancer	0.000106	0.000427	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—NDUFA13—thyroid cancer	0.000103	0.000417	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—AKT1—thyroid cancer	0.000103	0.000416	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—MINPP1—thyroid cancer	0.000103	0.000416	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	0.000103	0.000414	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—NDUFA13—thyroid cancer	0.000103	0.000414	CbGpPWpGaD
Irbesartan—JUN—Immune System—IFNA2—thyroid cancer	0.000102	0.000414	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CALCA—thyroid cancer	0.000102	0.000411	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TSHR—thyroid cancer	0.000102	0.00041	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PRKAR1A—thyroid cancer	0.0001	0.000404	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CHST14—thyroid cancer	9.72e-05	0.000392	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CHST14—thyroid cancer	9.64e-05	0.000389	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MEN1—thyroid cancer	9.56e-05	0.000386	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—HPGD—thyroid cancer	9.55e-05	0.000385	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—RXRA—thyroid cancer	9.48e-05	0.000383	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—NRG1—thyroid cancer	9.43e-05	0.000381	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—TP53—thyroid cancer	9.38e-05	0.000379	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CDK1—thyroid cancer	9.22e-05	0.000372	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—NDUFA13—thyroid cancer	8.76e-05	0.000354	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PTCH1—thyroid cancer	8.64e-05	0.000349	CbGpPWpGaD
Irbesartan—JUN—Immune System—NRG1—thyroid cancer	8.55e-05	0.000345	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—TPR—thyroid cancer	8.49e-05	0.000343	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TERT—thyroid cancer	8.47e-05	0.000342	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PRKAR1A—thyroid cancer	8.35e-05	0.000337	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CHST14—thyroid cancer	8.24e-05	0.000332	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—HIF1A—thyroid cancer	8.1e-05	0.000327	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—MINPP1—thyroid cancer	7.95e-05	0.000321	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—SST—thyroid cancer	7.91e-05	0.000319	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—HPGD—thyroid cancer	7.84e-05	0.000316	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—HPGD—thyroid cancer	7.77e-05	0.000314	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	7.74e-05	0.000313	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CALCA—thyroid cancer	7.61e-05	0.000307	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	7.57e-05	0.000306	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—NRG1—thyroid cancer	7.4e-05	0.000299	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—PTEN—thyroid cancer	7.36e-05	0.000297	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—NRAS—thyroid cancer	7.14e-05	0.000288	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CDK1—thyroid cancer	6.89e-05	0.000278	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—NDUFA13—thyroid cancer	6.76e-05	0.000273	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—BRAF—thyroid cancer	6.71e-05	0.000271	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TERT—thyroid cancer	6.65e-05	0.000268	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—HPGD—thyroid cancer	6.64e-05	0.000268	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—NRAS—thyroid cancer	6.56e-05	0.000265	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CHST14—thyroid cancer	6.36e-05	0.000257	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—HIF1A—thyroid cancer	6.36e-05	0.000257	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—SLC5A5—thyroid cancer	6.35e-05	0.000257	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	6.3e-05	0.000254	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—KRAS—thyroid cancer	6.14e-05	0.000248	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PPARG—thyroid cancer	5.98e-05	0.000242	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	5.95e-05	0.00024	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—KRAS—thyroid cancer	5.65e-05	0.000228	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—NRAS—thyroid cancer	5.6e-05	0.000226	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—NRG1—thyroid cancer	5.53e-05	0.000223	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—TPR—thyroid cancer	5.48e-05	0.000221	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PRKAR1A—thyroid cancer	5.39e-05	0.000218	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	5.38e-05	0.000217	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—RXRA—thyroid cancer	5.34e-05	0.000216	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—BRAF—thyroid cancer	5.26e-05	0.000212	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—HRAS—thyroid cancer	5.22e-05	0.000211	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	5.19e-05	0.00021	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—HPGD—thyroid cancer	5.12e-05	0.000207	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—AKT1—thyroid cancer	5.08e-05	0.000205	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TERT—thyroid cancer	4.96e-05	0.0002	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CCND1—thyroid cancer	4.89e-05	0.000198	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	4.89e-05	0.000197	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—KRAS—thyroid cancer	4.82e-05	0.000195	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—HRAS—thyroid cancer	4.8e-05	0.000194	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—HIF1A—thyroid cancer	4.75e-05	0.000192	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—PTEN—thyroid cancer	4.72e-05	0.000191	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PTGS2—thyroid cancer	4.71e-05	0.00019	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—AKT1—thyroid cancer	4.61e-05	0.000186	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—TPR—thyroid cancer	4.5e-05	0.000182	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—TPR—thyroid cancer	4.46e-05	0.00018	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PRKAR1A—thyroid cancer	4.43e-05	0.000179	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PRKAR1A—thyroid cancer	4.39e-05	0.000177	CbGpPWpGaD
Irbesartan—JUN—Immune System—PTEN—thyroid cancer	4.28e-05	0.000173	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—AKT1—thyroid cancer	4.24e-05	0.000171	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—NRAS—thyroid cancer	4.21e-05	0.00017	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PTEN—thyroid cancer	4.11e-05	0.000166	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—SLC5A5—thyroid cancer	4.1e-05	0.000166	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—HRAS—thyroid cancer	4.1e-05	0.000165	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—AKT1—thyroid cancer	3.98e-05	0.000161	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	3.98e-05	0.000161	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—BRAF—thyroid cancer	3.93e-05	0.000159	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	3.85e-05	0.000155	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CCND1—thyroid cancer	3.84e-05	0.000155	CbGpPWpGaD
Irbesartan—JUN—Immune System—NRAS—thyroid cancer	3.82e-05	0.000154	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—TPR—thyroid cancer	3.81e-05	0.000154	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PRKAR1A—thyroid cancer	3.75e-05	0.000151	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PTEN—thyroid cancer	3.71e-05	0.00015	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—KRAS—thyroid cancer	3.63e-05	0.000146	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—AKT1—thyroid cancer	3.62e-05	0.000146	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—RXRA—thyroid cancer	3.45e-05	0.000139	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	3.4e-05	0.000137	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PPARG—thyroid cancer	3.37e-05	0.000136	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—SLC5A5—thyroid cancer	3.37e-05	0.000136	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	3.35e-05	0.000135	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—SLC5A5—thyroid cancer	3.34e-05	0.000135	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—NRAS—thyroid cancer	3.31e-05	0.000134	CbGpPWpGaD
Irbesartan—JUN—Immune System—KRAS—thyroid cancer	3.29e-05	0.000133	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TP53—thyroid cancer	3.22e-05	0.00013	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	3.13e-05	0.000126	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—HRAS—thyroid cancer	3.08e-05	0.000124	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—TPR—thyroid cancer	2.94e-05	0.000119	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	2.89e-05	0.000117	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CCND1—thyroid cancer	2.87e-05	0.000116	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—SLC5A5—thyroid cancer	2.85e-05	0.000115	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—KRAS—thyroid cancer	2.85e-05	0.000115	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—RXRA—thyroid cancer	2.83e-05	0.000114	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—RXRA—thyroid cancer	2.81e-05	0.000113	CbGpPWpGaD
Irbesartan—JUN—Immune System—HRAS—thyroid cancer	2.8e-05	0.000113	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PTEN—thyroid cancer	2.77e-05	0.000112	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.73e-05	0.00011	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—AKT1—thyroid cancer	2.72e-05	0.00011	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2.67e-05	0.000108	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PTGS2—thyroid cancer	2.65e-05	0.000107	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TP53—thyroid cancer	2.53e-05	0.000102	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—NRAS—thyroid cancer	2.47e-05	9.98e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—AKT1—thyroid cancer	2.47e-05	9.97e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—HRAS—thyroid cancer	2.42e-05	9.77e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—RXRA—thyroid cancer	2.4e-05	9.68e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—AKT1—thyroid cancer	2.37e-05	9.55e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.33e-05	9.42e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PTEN—thyroid cancer	2.31e-05	9.34e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—SLC5A5—thyroid cancer	2.2e-05	8.89e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PPARG—thyroid cancer	2.18e-05	8.79e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—AKT1—thyroid cancer	2.14e-05	8.63e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—KRAS—thyroid cancer	2.13e-05	8.59e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TP53—thyroid cancer	1.89e-05	7.63e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—RXRA—thyroid cancer	1.85e-05	7.47e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—HRAS—thyroid cancer	1.81e-05	7.3e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PPARG—thyroid cancer	1.79e-05	7.22e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PPARG—thyroid cancer	1.77e-05	7.15e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PTGS2—thyroid cancer	1.71e-05	6.91e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—AKT1—thyroid cancer	1.6e-05	6.44e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PPARG—thyroid cancer	1.51e-05	6.11e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PTEN—thyroid cancer	1.49e-05	6.03e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PTGS2—thyroid cancer	1.41e-05	5.68e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PTGS2—thyroid cancer	1.39e-05	5.63e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—AKT1—thyroid cancer	1.33e-05	5.38e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PTEN—thyroid cancer	1.23e-05	4.95e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PTEN—thyroid cancer	1.22e-05	4.91e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PTGS2—thyroid cancer	1.19e-05	4.81e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PPARG—thyroid cancer	1.17e-05	4.72e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PTEN—thyroid cancer	1.04e-05	4.19e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PTGS2—thyroid cancer	9.19e-06	3.71e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—AKT1—thyroid cancer	8.61e-06	3.48e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PTEN—thyroid cancer	8.02e-06	3.24e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—AKT1—thyroid cancer	7.07e-06	2.85e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—AKT1—thyroid cancer	7.01e-06	2.83e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—AKT1—thyroid cancer	5.99e-06	2.42e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—AKT1—thyroid cancer	4.62e-06	1.87e-05	CbGpPWpGaD
